British Journal of Haematology · 2003 · 35 citations · 7 references
PharmacyHematologyImmunologyCancer ImmunologyChemotherapyMonoclonal AntibodiesAntibody CharacterizationB Cell BiologyCancer ImmunotherapyMonoclonal Antibody TherapyTherapeutic Antibody DevelopmentTherapeutic Monoclonal AntibodiesAnti-cd20 TherapyB-cell LeukemiaB-cell Malignancy TherapyChronic Lymphocytic Leukemia TherapyConfocal Laser Scanning MicroscopyMonoclonal Antibodies In CancerMonoclonal Antibodies In OncologyMonoclonal Antibody Therapeutics
B-cell chronic lymphocytic leukaemia (B-CLL) cannot be cured by conventional chemotherapy, therefore, toxin-linked therapeutic monoclonal antibodies (mAbs) are increasingly examined for their potential to improve clinical outcome. The current study aimed to identify mAbs that were internalized by the B-CLL cells of 14 patients, using both flow cytometry and confocal laser scanning microscopy. Anti-CD5, CD22 and CD40 mAbs were effectively taken up by B-CLL cells, whereas mAbs against CD19, CD20, CD23 and CD45 were not. This study may form a basis for further research to identify antibodies that may serve as carriers for toxins to treat B-CLL.
7
Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.
Oliver W. Press, Andrew G. Farr, K.I. Borroz et al. · PubMed · 1989 · 252 citations
Life Sciences, Immunology, Oncology +17
Maria J. Polyak, Julie P. Deans · Blood · 2002 · 156 citations · Full text